This article highlights clinical and economic factors associated with Demodex blepharitis as well as diagnostic complexities, limitations of traditional therapies, the safety and efficacy of the 1 ...

Dealing with red, itchy eyelids? The culprit could be a common mite. This article is sponsored by XDEMVY. Dr. Watson is a ...

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tarsus Pharmaceuticals (TARS – Research Report). The ...

This follows a successful 2024 for Tarsus, highlighted by the strong launch of XDEMVY, a treatment for Demodex blepharitis, generating over $113 million in sales. Tarsus is also pursuing ...

When problems arise, however, the mites can be controlled with simple treatments, experts say. Demodex mites often ... is ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...

Historically, patients with Demodex blepharitis simply had to "deal with ... Tarsus Pharmaceuticals is also on a treatment for rosacea around the eyes and a drug that could prevent Lyme disease.

Tarsus Pharmaceuticals, which has more than 100 of its 331 employees in Orange County, has plans to double its office space ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...